Rocketing demand, legal disputes, and the future of weight loss were all spurred by a new class of anti-obesity medications.

As Eli Lilly ends the year with Zepbound in good supply, TD Cowen analyst Steve Scala asked CEO David Ricks if the company ...

Shares of Eli Lilly finished Thursday 3% higher despite an earnings report that showed sales of its blockbuster GLP-1 ...

Evaluate’s latest analysis forecasts an $82 billion increase in major product revenues in 2025 – the largest annual growth ...

Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and ...

It can be hard to sate investors’ appetites, but if there’s two companies who should know how to do it, it’s these two.

New Orleans is known for its cuisine, and there's at least one chef in the Big Easy who is a big Eagles fan.

Despite heavy demand for its weight-loss and diabetes treatments, limited supply hobbled Eli Lilly's fourth-quarter sales.